PARK7/DJ1 antibody (ab37180)

Product Name 

PARK7/DJ1 antibody

Product type 

Primary antibodies

Description 

Rabbit polyclonal to PARK7/DJ1

Immunogen 

Synthetic peptide: GLILTSRGPG TSFEFALAIV EALNGKEVAA , corresponding to C terminal amino acids 150/189 of Human PARK7/DJ1
BLAST 'GLILTSRGPG TSFEFALAIV EALNGKEVAA QVKAPLVLKD ' with or

Reacts with 

Hu, Ms

Predicted to react 
(species key)

Rat, Cow, Hm
(Due to sequence homology)

Specificity 

This antibody is specific for DJ1.

Tested applications 
(see key)

IHC-P, IP, WB

Abreviews 

Customer reviews (see key)

Read about Abreviews (Read all Abreviews)

Application notes 
(see key)

Recommended dilutions
IHC-P: 1/500.
IP: Use 5µl/ml, or 1/200.
WB: 1/2000. Detects a band of approximately 25 kDa (predicted molecular weight: 20 kDa).

Note: ab37180 has only been tested on transfected lysates, both human and mouse. It is unknown if it will work on endogenous samples.


Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.

Positive control 
(see definition)

human cortex, DJ1 transfected 293 cell lysates

Cellular localization 

Cytoplasmic, Mitochondrial and Nuclear

Research areas 

Cancer >> Signal transduction >> G protein signaling >> Small G proteins >> Other
Chromatin and Nuclear Signaling >> Chromatin Binding Proteins >> DNA / RNA binding
Signal Transduction >> Signaling Pathway >> G Protein Signaling >> Small G Proteins >> Regulators
Neuroscience >> Neurology process >> Neurodegenerative disease >> Parkinson's disease >> Parkin / PARK

Relevance 

PARK7/DJ1 is a ubiquitously expressed protein involved in various cellular processes including cell proliferation, RNA-binding, and oxidative stress. The protein has been found to colocalize within a subset of pathologic tau inclusions in a diverse group of neurodegenerative disorders known as tauopathies (Rizzu et al. 2004). Defects in PARK7/DJ1 are the cause of autosomal recessive early-onset Parkinson's disease 7 (PARK7). Parkinson's disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years. The disease is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK7 is characterized by onset before 40 years and slow progression. It has also been suggested that PARK7/DJ1 is a mitogen dependent oncogene product involved in Ras related signal transduction pathways.

Database links 

Raised in 

Rabbit

Clonality 

Polyclonal

Isotype 

IgG

Purity 

Whole antiserum

Storage buffer 

Preservative: None
Constituents: Whole serum

Form 

Liquid

Concentration 

Concentration not determined - why is this?

Storage instructions 

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

See below for PARK7/DJ1 antibody images, references, products related to ab37180 and other tools.

PARK7/DJ1 antibody images:

References for PARK7/DJ1 antibody (ab37180)

  This product has been used in: (two most recent references)

Giaime E et al. Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6. Cell Death Differ 17:158-69 (2010). WB. PubMed: 19680261

Jia X et al. Peroxiredoxin-6--a potential protein marker for meat tenderness in bovine longissimus thoracis muscle. J Anim Sci 87:2391-9 (2009). PubMed: 19359513
If you publish research using ab37180 please let us know so that we can cite the reference on this datasheet.

Customer reviews (feedback) regarding PARK7/DJ1 antibody

Customer FAQs regarding PARK7/DJ1 antibody

Protocols for PARK7/DJ1 antibody

Price and availability of products related to PARK7/DJ1 antibody

PARK7/DJ1 antibody - related products: